Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma

Journal of Cancer Research and Clinical Oncology(2025)10.1007/s00432-025-06269-9Source: DataRank Database

High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma is a research paper published in Journal of Cancer Research and Clinical Oncology (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

geo bioproject cellosaurus rrid

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.00)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Leon McSwain,Wei Zhou ORCID,Adam I. Marcus ORCID,Haian Fu ORCID,Suresh S. Ramalingam ORCID

Live enrichment

PubMed:40715535 PMC:PMC12297223 OpenAlex:https://openalex.org/W4412670029

National Cancer Institute

Grant: R01CA194027

National Cancer Institute

Grant: P50CA217691

National Cancer Institute

Grant: P30CA138292

NCI NIH HHS

Grant: P01 CA257906

NCATS NIH HHS

Grant: UL1 TR002378

National Institutes of Health

Grant: 5R01CA194027-03

Developing a pharmacologic approach to treat LKB1 mutant NSCLC patients

National Institutes of Health

Grant: 5P30CA138292-11

Winship Cancer Institute Cancer Center Support Grant

National Institutes of Health

Grant: 5UL1TR002378-09

Georgia Clinical & Translational Science Alliance (Georgia CTSA)

National Institutes of Health

Grant: 1P50CA217691-01A1

Emory University Lung Cancer SPORE

FWCI

0.00

Citation Percentile

0.1%

goldLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s00432-025-06269-9.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00432-025-06269-9.pdf

publisherhttps://link.springer.com/article/10.1007/s00432-025-06269-9

journalhttps://doi.org/10.1007/s00432-025-06269-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40715535

Fields of Study

RNA modifications and cancerCancer-related molecular mechanisms researchFerroptosis and cancer prognosis03 medical and health sciences0302 clinical medicineHumansProtein Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesLung NeoplasmsAdenocarcinoma of LungMutationBiomarkers, TumorDrug Resistance, NeoplasmImmunotherapyCell ProliferationGene Expression Regulation, NeoplasticA549 Cells

MeSH Terms

A549 CellsAdenocarcinoma of LungAMP-Activated Protein Kinase KinasesHumansImmunotherapyLung NeoplasmsMutationBiomarkers, TumorGene Expression Regulation, NeoplasticProtein Serine-Threonine KinasesDrug Resistance, NeoplasmCell Proliferation

Keywords

ImmunotherapySTK11AdenocarcinomaHematologyMedicineInternal medicineLungMutationOncologyCancer researchCancerBiologyGeneticsGeneInvasionLung adenocarcinomaPD-L1Per1Lkb1Cd274Research

Sustainable Development Goals

SDG 0: Good health and well-being

High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma

FAIR Checklist

Authors (8)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)